Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cybin Inc.

< Previous 1 2 3 4 5 6 7 8 Next >
Cybin Files Two Additional International Patent Applications in Support of the Company’s Research Phase Programs
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Files 14th Patent Application Further Strengthening its IP Portfolio and Receives a Favorable Patent Claim Opinion
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Election of Theresa Firestone as Director, Results of Shareholders’ Meeting and Adoption of Shareholder Rights Plan
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Announces 2021 First Quarter Financial Results and Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
CORRECTING and REPLACING Cybin Announces Additional Adelia Milestone Achievements
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional Adelia Milestone Achievements
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present at Canaccord Genuity’s 41st Annual Growth Conference on August 10th
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Commence Trading on the NYSE American on August 5
From Cybin Inc.
Via Business Wire
Cybin Receives Final Approval to Commence Trading on the NYSE American on or About August 5
From Cybin Inc.
Via Business Wire
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common Shares
From Cybin Inc.
Via Business Wire
Cybin Announces Conditional Listing Approval from NYSE American
From Cybin Inc.
Via Business Wire
Cybin Files its 13th Patent Application and Announces Digital Therapeutics Strategy
From Cybin Inc.
Via Business Wire
Cybin to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on July 13th
From Cybin Inc.
Via Business Wire
Cybin Expands to Europe and Provides Update on Intellectual Property Portfolio
From Cybin Inc.
Via Business Wire
Cybin Enters into Collaboration Agreement with Greenbrook TMS to Establish Mental Health Centers of Excellence
From Cybin Inc.
Via Business Wire
Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Cybin Inc. Releases Annual Financials and Provides Business Highlights
From Cybin Inc.
Via Business Wire
Cybin to Participate in Grizzle Psychedelics Con on June 28th
From Cybin Inc.
Via Business Wire
Cybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has Joined Clinical Advisory Board
From Cybin Inc.
Via Business Wire
Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study
From Cybin Inc.
Via Business Wire
Cybin to Present at the Emerging Growth Conference on June 23rd
From Cybin Inc.
Via Business Wire
Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004
From Cybin Inc.
Via Business Wire
Cybin to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th
From Cybin Inc.
Via Business Wire
Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy
From Cybin Inc.
Via Business Wire
Cybin to Present at the 2021 LD Micro Invitational XI on June 10, 2021
From Cybin Inc.
Via Business Wire
Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine’s Psychedelic Effects on Cerebral Cortex Hemodynamics
From Cybin Inc.
Via Business Wire
Cybin to Present at the Jefferies Virtual Healthcare Conference 2021
From Cybin Inc.
Via Business Wire
Cybin Files an International Patent Application Further Strengthening its Psychedelic Derivative Drug Development Candidates Across 153 Global Jurisdictions
From Cybin Inc.
Via Business Wire
Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms
From Cybin Inc.
Via Business Wire
Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.